Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.
González-Lama Y, López-San Román A, Marín-Jiménez I, Casis B, Vera I, Bermejo F, Pérez-Calle JL, Taxonera C, Martínez-Silva F, Menchén L, Martínez-Montiel P, Calvo M, Carneros JA, López P, Mendoza JL, Milicua JM, Huerta A, Sánchez F, Abreu L, López-Palacios N, Maté J, Gisbert JP; Group for the Study of Inflammatory Bowel Diseases from Madrid (ENICMAD). González-Lama Y, et al. Among authors: casis b. Gastroenterol Hepatol. 2008 Aug-Sep;31(7):421-6. doi: 10.1157/13125587. Gastroenterol Hepatol. 2008. PMID: 18783686
Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response.
Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A, Taxonera C, Casis B, Tabernero S, Bermejo F, Martinez-Silva F, Mendoza JL, Martinez-Montiel P, Carneros JA, Sanchez F, Maté J, Gisbert JP; Group for the Study of Inflammatory Bowel Diseases from Madrid. Gonzalez-Lama Y, et al. Among authors: casis b. Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1609-14. Hepatogastroenterology. 2008. PMID: 19102352
Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience.
Fortea-Ormaechea JI, González-Lama Y, Casis B, Chaparro M, López Serrano P, Van Domselaar M, Bermejo F, Pajares R, Ponferrada A, Vera MI, Martínez Montiel P, Gisbert JP, Pérez-Calle JL, López San Román A, Abreu L, Menchén LA, Marín-Jiménez I. Fortea-Ormaechea JI, et al. Among authors: casis b. Gastroenterol Hepatol. 2011 Aug-Sep;34(7):443-8. doi: 10.1016/j.gastrohep.2011.04.001. Epub 2011 Jul 2. Gastroenterol Hepatol. 2011. PMID: 21724297
Predictors of response to infliximab in patients with fistulizing Crohn's disease.
Luna-Chadid M, Pérez Calle JL, Mendoza JL, Vera MI, Bermejo AF, Sánchez F, López San Román A, Froilán C, González-Lara V, García-Paredes J, Fernández-Blanco I, Abreu L, Casis B, Solís Herruzo JA, Gisbert JP, Maté Jiménez J. Luna-Chadid M, et al. Among authors: casis b. Rev Esp Enferm Dig. 2004 Jun;96(6):379-81; 382-4. doi: 10.4321/s1130-01082004000600003. Rev Esp Enferm Dig. 2004. PMID: 15230667 Free article. English, Spanish.
Intensification of infliximab therapy in Crohn's disease: efficacy and safety.
M Chaparro, Martínez-Montiel P, Van Domselaar M, Bermejo F, Pérez-Calle JL, Casis B, Román AL, Algaba A, Maté J, Gisbert JP. M Chaparro, et al. Among authors: casis b. J Crohns Colitis. 2012 Feb;6(1):62-7. doi: 10.1016/j.crohns.2011.07.005. Epub 2011 Aug 20. J Crohns Colitis. 2012. PMID: 22261529
Incidence, management, and course of cancer in patients with inflammatory bowel disease.
Algaba A, Guerra I, Marín-Jiménez I, Quintanilla E, López-Serrano P, García-Sánchez MC, Casis B, Taxonera C, Moral I, Chaparro M, Martín-Rodríguez D, Martín-Arranz MD, Manceñido N, Menchén L, López-Sanromán A, Castaño Á, Bermejo F. Algaba A, et al. Among authors: casis b. J Crohns Colitis. 2015 Apr;9(4):326-33. doi: 10.1093/ecco-jcc/jjv032. Epub 2015 Feb 16. J Crohns Colitis. 2015. PMID: 25687203
Health care costs of complex perianal fistula in Crohn's disease.
Chaparro M, Zanotti C, Burgueño P, Vera I, Bermejo F, Marín-Jiménez I, Yela C, López P, Martín MD, Taxonera C, Botella B, Pajares R, Ponferrada A, Calvo M, Algaba A, Pérez L, Casis B, Maté J, Orofino J, Lara N, García-Losa M, Badia X, Gisbert JP. Chaparro M, et al. Among authors: casis b. Dig Dis Sci. 2013 Dec;58(12):3400-6. doi: 10.1007/s10620-013-2830-7. Epub 2013 Sep 13. Dig Dis Sci. 2013. PMID: 24026400
Infliximab-related hepatitis: a case study and literature review.
Colina F, Molero A, Casís B, Martínez-Montiel P. Colina F, et al. Among authors: casis b. Dig Dis Sci. 2013 Nov;58(11):3362-7. doi: 10.1007/s10620-013-2698-6. Epub 2013 May 5. Dig Dis Sci. 2013. PMID: 23645381 Review. No abstract available.
Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units.
Calvet X, Panés J, Alfaro N, Hinojosa J, Sicilia B, Gallego M, Pérez I, Lázaro y de Mercado P, Gomollón F; Members of Consensus Group; Aldeguera X, Alós R, Andreu M, Barreiro M, Bermejo F, Casis B, Domenech E, Espín E, Esteve M, García-Sánchez V, López-Sanromán A, Martínez-Montiel P, Luis Mendoza J, Gisbert JP, Vera M, Dosal A, Sánchez E, Marín L, Sanromán L, Pinilla P, Murciano F, Torrejón A, Ramón García J, Ortega M, Roldán J. Calvet X, et al. Among authors: casis b. J Crohns Colitis. 2014 Mar;8(3):240-51. doi: 10.1016/j.crohns.2013.10.010. Epub 2013 Dec 2. J Crohns Colitis. 2014. PMID: 24295646
Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis.
Taxonera C, Fernández-Aceñero MJ, Olivares D, Calvo M, Casis B, Bermejo F, López Serrano P, Iborra M, Mesonero F, Boscá Watts M, Díaz Del Arco C, Vera I, Olivares S, Algaba A, Alba C. Taxonera C, et al. Among authors: casis b. Aliment Pharmacol Ther. 2022 Aug;56(4):614-624. doi: 10.1111/apt.16964. Epub 2022 May 4. Aliment Pharmacol Ther. 2022. PMID: 35509152
29 results